<code id='39CB48971F'></code><style id='39CB48971F'></style>
    • <acronym id='39CB48971F'></acronym>
      <center id='39CB48971F'><center id='39CB48971F'><tfoot id='39CB48971F'></tfoot></center><abbr id='39CB48971F'><dir id='39CB48971F'><tfoot id='39CB48971F'></tfoot><noframes id='39CB48971F'>

    • <optgroup id='39CB48971F'><strike id='39CB48971F'><sup id='39CB48971F'></sup></strike><code id='39CB48971F'></code></optgroup>
        1. <b id='39CB48971F'><label id='39CB48971F'><select id='39CB48971F'><dt id='39CB48971F'><span id='39CB48971F'></span></dt></select></label></b><u id='39CB48971F'></u>
          <i id='39CB48971F'><strike id='39CB48971F'><tt id='39CB48971F'><pre id='39CB48971F'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          entertainment

          author:comprehensive    - browse:787
          Stock exchange
          Drew Angerer/Getty Images

          Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

          On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

          advertisement

          “We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus